Dr. Alexander R. Duncan, also known as Alex, BSc, MA, Ph.D., has been Chief Technology Officer at Agenus Inc. since January 27, 2016 and its Head of Research since September 26, 2017. Dr. Duncan served as Vice President of Preclinical Development of Agenus Inc. since July 2015 until January 2016. Dr. Duncan served as Senior Vice President of Research and Development of Affitech AS since September 2009 and served as its Chief Scientific Officer and Member of Executive Board. Dr. Duncan is a leading antibody research scientist and business leader. He served as Senior Vice President Drug Discovery at MedImmune Limited. He served as Vice President - Drug Discovery of MedImmune Limited. Dr. Duncan served as Vice President and Senior Vice President of Drug Discovery of Cambridge Antibody Technology Group PLC. and has been with Cambridge Antibody Technology Group PLC since 1994. He led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT), through its integration with Medimmune. Dr. Duncan has been with CAT since 1994. He served as Vice President Drug Discovery, he held the position of Head of Antibody Engineering. At Astra Zeneca, he was a member of AZ Discovery senior management team and SVPBiopharmaceuticals. He served as Member of Scientific Advisory Board at MedImmune Limited. He served as a Director of ExpreS2ion Biotechnologies ApS. Before joining CAT, he was a Research Fellow at the University of California and prior to that, a Lucille P Markey Visiting Fellow also at the University of California. Dr. Duncan gained his PhD in Dr. Sir Greg Winter’slaboratory at the MRC Laboratory of Molecular Biology, University of Cambridgeand held post-doctoral positions at the University of California San Diego.